Mad2L1 Antibody [L3N17]

Catalog No.: F4911

Application: Reactivity: Human

当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000

Application
WB, IHC

Source
Mouse Monoclonal Antibody

Reactivity
Human

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
24 kDa 24 kDa
^*なぜ予測分子量と実際の分子量が異なるのか？下記の原因により、実際の分子量が予測と異なる：タンパク質の翻訳後修飾（リン酸化/糖鎖付加），スプライシングバリアント，イソフォーム，相対的な電荷，ポリマー。

Datasheet & SDS

生物学的記述

Specificity
Mad2L1 Antibody [L3N17] detects endogenous levels of total Mad2L1 protein.

Clone
L3N17

Synonym(s)
MAD2, MAD2L1, Mitotic spindle assembly checkpoint protein MAD2A, HsMAD2, Mitotic arrest deficient 2-like protein 1, MAD2-like protein 1

Background
Mad2L1, a pivotal component of the spindle assembly checkpoint (SAC) within the MAD/BUB protein family, safeguards genomic integrity by delaying anaphase onset until bi-orientation of all kinetochores on the mitotic spindle. The protein adopts open (O-Mad2) and closed (C-Mad2) conformations, with C-Mad2 forming a stable tetramer with Mad1 at unattached kinetochores to catalyze O-Mad2 conversion and template Cdc20 binding, generating the mitotic checkpoint complex (MCC) comprising Mad2, BubR1, Bub3, and Cdc20. MCC binding to APC/C inhibits its E3 ubiquitin ligase activity, stabilizing securin and cyclin B1 to prevent separase activation and sister chromatid separation; microtubule attachment and tension relieve SAC via Aurora B-mediated stripping of Knl1 and PP1 recruitment, disassembling MCC and licensing anaphase. Mad2 overexpression destabilizes microtubule plus ends through EB1 interaction, promoting microtubule catastrophe and merotelic attachments independent of checkpoint signaling, while nuclear Mad2 binds E2F1 to repress transcription. Ubiquitously expressed but elevated in proliferative tissues, Mad2L1 ensures faithful chromosome segregation critical for development and tissue renewal. Dysregulation drives chromosomal instability (CIN) hallmarking cancers, where overexpression correlates with aneuploidy, proliferation, poor prognosis, and chemoresistance in oral, gastric, and other carcinomas; silencing induces senescence, underscoring therapeutic potential via SAC modulation.

Background

Mad2L1, a pivotal component of the spindle assembly checkpoint (SAC) within the MAD/BUB protein family, safeguards genomic integrity by delaying anaphase onset until bi-orientation of all kinetochores on the mitotic spindle. The protein adopts open (O-Mad2) and closed (C-Mad2) conformations, with C-Mad2 forming a stable tetramer with Mad1 at unattached kinetochores to catalyze O-Mad2 conversion and template Cdc20 binding, generating the mitotic checkpoint complex (MCC) comprising Mad2, BubR1, Bub3, and Cdc20. MCC binding to APC/C inhibits its E3 ubiquitin ligase activity, stabilizing securin and cyclin B1 to prevent separase activation and sister chromatid separation; microtubule attachment and tension relieve SAC via Aurora B-mediated stripping of Knl1 and PP1 recruitment, disassembling MCC and licensing anaphase. Mad2 overexpression destabilizes microtubule plus ends through EB1 interaction, promoting microtubule catastrophe and merotelic attachments independent of checkpoint signaling, while nuclear Mad2 binds E2F1 to repress transcription. Ubiquitously expressed but elevated in proliferative tissues, Mad2L1 ensures faithful chromosome segregation critical for development and tissue renewal. Dysregulation drives chromosomal instability (CIN) hallmarking cancers, where overexpression correlates with aneuploidy, proliferation, poor prognosis, and chemoresistance in oral, gastric, and other carcinomas; silencing induces senescence, underscoring therapeutic potential via SAC modulation.

References
[1] Teixeira JH, et al. Oral Dis. 2015 Sep;21(6):713-20. [2] Ballister ER, et al. Curr Biol. 2012 Apr 10;22(7):R233-5.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%